Beta Bionics, Inc. (BBNX) NASDAQ
10.39
+0.28(+2.77%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
10.39
+0.28(+2.77%)
Currency In USD
| Previous Close | 10.11 |
| Open | 10.3 |
| Day High | 10.62 |
| Day Low | 10.2 |
| 52-Week High | 32.71 |
| 52-Week Low | 8.89 |
| Volume | 888,745 |
| Average Volume | 1.29M |
| Market Cap | 461.13M |
| PE | -5.74 |
| EPS | -1.81 |
| Moving Average 50 Days | 16.5 |
| Moving Average 200 Days | 20.07 |
| Change | 0.28 |
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Car
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
GlobeNewswire Inc.
Jan 15, 2026 9:03 PM GMT
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 fi
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
GlobeNewswire Inc.
Jan 08, 2026 9:04 PM GMT
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metri